Nurexone Biologic Inc
F:J90
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nurexone Biologic Inc
Other Equity
Nurexone Biologic Inc
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nurexone Biologic Inc
F:J90
|
Other Equity
-$73k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Enerflex Ltd
TSX:EFX
|
Other Equity
-CA$199m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
TerraVest Industries Inc
TSX:TVK
|
Other Equity
-CA$10m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-53%
|
CAGR 10-Years
20%
|
|
|
CES Energy Solutions Corp
TSX:CEU
|
Other Equity
CA$202.5m
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
|
Secure Energy Services Inc
TSX:SES
|
Other Equity
CA$92m
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
H
|
HydroGraph Clean Power Inc
CNSX:HG
|
Other Equity
-$326.1k
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
See Also
What is Nurexone Biologic Inc's Other Equity?
Other Equity
-73k
USD
Based on the financial report for Dec 31, 2024, Nurexone Biologic Inc's Other Equity amounts to -73k USD.
What is Nurexone Biologic Inc's Other Equity growth rate?
Other Equity CAGR 1Y
0%
Over the last year, the Other Equity growth was 0%.
